Compare BridgeBio Pharma Inc (BBIO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Zoetis Inc — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Zoetis Inc trades at $74.9 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.81% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ZTS | |
|---|---|---|
Market Cap | $16.36B | $31.14B |
Sector | Health | Health |
52-Week High | $90.17 | $156.76 |
52-Week Low | $47.29 | $71.91 |
Enterprise Value | $18.14B | $38.70B |
Dividend Yield | — | 2.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
